Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.

Burger, R A

Burger, R A.

Affiliation

Burger RA; Department of Surgical Oncology, Section of Gynecologic Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. robert.burger@fccc.edu

Ann Oncol ; 22 Suppl 8: viii65-viii68, 2011 Dec.

Article in En | MEDLINE | ID: mdl-22180405

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Neoplasm Recurrence, Local/drug therapy; Neoplasms, Glandular and Epithelial/drug therapy; Ovarian Neoplasms/drug therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local/blood supply; Neoplasms, Glandular and Epithelial/blood supply; Neoplasms, Glandular and Epithelial/pathology; Ovarian Neoplasms/blood supply; Ovarian Neoplasms/pathology; Randomized Controlled Trials as Topic; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplasms, Glandular and Epithelial / Angiogenesis Inhibitors / Antibodies, Monoclonal, Humanized / Neoplasm Recurrence, Local Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google